3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
77.7
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2022-12-31
Compliance Officer - 2021-12-31
Investor Relations Contact - 2018-07-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/25 Issuer sale

Director

85,011 0.1134%
7/1/25 Issuer sale

Chief Financial Officer

738,955 0.9861%
7/1/25 Issuer sale

Chief Technology Officer

151,946 0.2028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--% - - 3.54B
+0.43%+6.59%+53.41%+103.85% 1,120B
+0.90%-2.25%+33.02%+62.23% 616B
+0.71%+3.24%+25.81%+93.86% 504B
-0.13%+5.98%+32.91%+50.39% 367B
+0.52%+0.24%+73.92%+40.15% 360B
-0.95%+4.70%+19.51%+43.00% 288B
-1.98%+3.73%-0.86%+13.43% 258B
-0.35%+4.25%+46.21%+50.76% 234B
-0.75%+3.32%+32.53%+97.21% 194B
Average -0.16%+3.61%+35.16%+61.65% 437.88B
Weighted average by Cap. +0.13%+3.83%+39.18%+71.44%
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - SpringWorks Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SWTX Stock